Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advanced pancreatic cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10:511–8.
   PubMed Web of Science ®Google Scholar
• Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, et al. Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007;34:521–9.
   PubMed Web of Science ®Google Scholar
• Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2012; 82:e595–601.
   Google Scholar
• Sangalli, G, Passoni P, Cattaneo GM, Broggi S, Bettinardi V, Reni M, et al. Planning design of locally advanced pancreatic carcinoma using 4DCT and IMRT/IGRT technologies. Acta Oncol 2011;50:72–80.
   PubMed Web of Science ®Google Scholar
• Landry JC, Yang GY, Ting JY, Staley CA, Torres W, Esiashvili N, et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): Employing dose- volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim 2002;27:121–9.
   PubMedGoogle Scholar
• Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;84:1166–71.
   PubMed Web of Science ®Google Scholar
• Eppinga W, Lagerwaard F, Verbakel W, Slotman B, Senan S. Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 2010;186:382–7.
   PubMed Web of Science ®Google Scholar
• Ali AN, Dhabaan AH, Jarrio CS, Siddiqi AK, Landry JC. Dosimetric comparison of volumetric modulated arc therapy and intensity-modulated radiation therapy for pancreatic malignancies. Med Dosim 2012;37:271–5.
   PubMed Web of Science ®Google Scholar
• Vieillot S, Azria D, Riou O, Moscardo CL, Dubois JB, Ailleres N, et al. Bilateral kidney preservation by volumetric-modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies. Radiat Oncol 2011;6:147.
   PubMedGoogle Scholar
• Scorsetti M, Bignardi M, Alongi F, Fogliata A, Mancosu P, Navarria P, et al. Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: Feasibility and clinical preliminary results. Acta Oncol 2011;50:528–38.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Shibuya K, Matsuo Y, Nakamura M, Shiinoki T, Mizowaki T, et al. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;84:369–75.
   PubMed Web of Science ®Google Scholar
• Liu M, Moiseenko V, Agranovich A, Karvat A, Kwan W, Saleh ZH, et al. Normal tissue complication probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: A test of the QUANTEC-favored model. Int J Radiat Oncol Biol Phys 2010;78: S45–6.
   Google Scholar
• Fokas E, Eccles C, Patel N, Chu K-Y, Warren S, McKenna WG, et al. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Radiother Oncol 2013;107: 200–6.
   PubMed Web of Science ®Google Scholar
• Eccles C, Vallis KA, McKenna W, Brunner T, editors. 1354 poster. Potential advantages and tradeoffs of intensity modulated radiotherapy for locally advanced pancreas cancer (including elective nodal volumes). Radiother Oncol 2011; 99(Suppl 1):S506.
   Google Scholar
• Pan CC, Dawson LA, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced gastric and duodenal bleeds using the Lyman-Kutcher-Burman model. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl):S217–8.
   PubMedGoogle Scholar
• Huang J, Robertson JM, Ye H, Margolis J, Nadeau L, Yan D. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2012;83:1120–5.
   PubMed Web of Science ®Google Scholar
• Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 2003;69:201–7.
   PubMed Web of Science ®Google Scholar
• Li XA, Alber M, Deasy JO, Jackson A, Jee KWK, Marks LB, et al. The use and QA of biologically related models for treatment planning: Short report of the TG-166 of the therapy physics committee of the AAPM(a). Med Phys 2012;39: 1386–409.
   PubMed Web of Science ®Google Scholar
• Sanchez-Nieto B, Nahum AE. BIOPLAN: Software for the biological evaluation of. Radiotherapy treatment plans. Med Dosim 2000;25:71–6.
   PubMedGoogle Scholar
• Yovino S, Maidment BW, 3rd, Herman JM, Pandya N, Goloubeva O, Wolfgang C, et al. Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys 2012;83:916–20.
   PubMed Web of Science ®Google Scholar
• Caravatta L, Sallustio G, Pacelli F, Padula GD, Deodato F, Macchia G, et al. Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiat Oncol 2012;7:86.
   PubMed Web of Science ®Google Scholar
• Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76:S10–9.
   PubMed Web of Science ®Google Scholar
• Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic-function. Int J Radiat Oncol Biol Phys 1991;21:123–35.
   PubMed Web of Science ®Google Scholar